Rani Therapeutics Holdings, Inc. (RANI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol RANI
- Company Rani Therapeutics Holdings, Inc.
- Price $1.82
- Changes Percentage -12.92
- Change -0.27
- Day Low $1.77
- Day High $2.18
- Year High $3.87
- Year Low $0.39
- Market Cap $132,846,871
- Price Avg 50 EMA (D) $0.71
- Price Avg 200 EMA (D) $0.93
- Exchange NASDAQ
- Volume 12,411,904
- Average Volume 14,284,942
- Open $2.03
- Previous Close $2.09
- EPS -0.9
- PE -2.02
- Earnings Announcement 2025-11-13 20:00:00
- Shares Outstanding $72,992,786
Company brief: RANI THERAPEUTICS HOLDINGS, INC. (RANI )
- Healthcare
- Biotechnology
- Mr. Talat Imran
- https://www.ranitherapeutics.com
- US
- N/A
- 07-30-2021
- US7530181004
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.